Syfovre and Izervay Treatment for Dry Macular Degeneration in Sarasota, FL

Syfovre and Izervay are FDA-approved injectable medications used to treat geographic atrophy, an advanced form of dry macular degeneration. They are designed to slow the progression of retinal cell loss that leads to enlarging blind spots in central vision.

Geographic atrophy occurs when the light-sensitive cells in the macula gradually deteriorate. Until recently, there were no approved treatments to slow this process. Syfovre and Izervay are the first medications proven to reduce the rate at which these blind spots expand.

These treatments do not restore vision that has already been lost, but they can help preserve remaining central vision for a longer period of time in patients with advanced dry AMD.

These treatments are not indicated for early or intermediate dry macular degeneration and are specifically used for patients with geographic atrophy in more advanced stages of the disease.

Geographic atrophy is an advanced stage of dry macular degeneration in which areas of the retina gradually lose their light-sensitive cells. As these cells deteriorate, permanent blind spots develop in the center of vision.

In geographic atrophy, the retinal cells responsible for detailed sight slowly die, a process known as atrophy. Over time, these areas of damage expand, causing increasing difficulty with reading, driving, recognizing faces, and performing other activities that rely on central vision.

Unlike wet macular degeneration, geographic atrophy does not involve abnormal blood vessel growth or bleeding. Instead, it represents progressive cell loss within the macula itself.

Geographic atrophy is irreversible, meaning the damaged retinal tissue cannot recover. However, newer treatments such as complement inhibitor injections are designed to slow the enlargement of these atrophic areas and help preserve remaining vision for as long as possible.

Syfovre and Izervay work by blocking part of the complement system, a component of the body’s immune response that plays a role in the progression of geographic atrophy.

In dry macular degeneration, overactivation of the complement pathway contributes to inflammation and gradual destruction of retinal cells. This ongoing immune activity accelerates the enlargement of atrophic areas in the macula.

Syfovre and Izervay are complement inhibitors. By reducing complement activity inside the eye, these medications slow the rate at which retinal cells are damaged. Clinical trials have shown that both drugs reduce the growth of geographic atrophy lesions by approximately 20 percent over two years compared to no treatment.

These medications do not reverse existing damage or restore lost vision. Their purpose is to preserve remaining central vision by slowing further progression of retinal cell loss.

Syfovre and Izervay have been shown in clinical trials to slow the progression of geographic atrophy by approximately 20 percent over two years compared to no treatment. Their primary benefit is reducing how quickly blind spots enlarge in patients with advanced dry macular degeneration.

Both medications were studied in large, controlled trials where patients received regular injections over a two-year period. The results demonstrated a measurable reduction in the growth rate of atrophic areas in the macula. Slowing this progression may help preserve reading and driving vision for a longer period of time.

It is important to understand that these medications do not restore vision that has already been lost. Their benefit lies in protecting remaining retinal cells and delaying further decline.

Individual results vary depending on disease stage, location of geographic atrophy, and overall retinal health. A retina specialist can determine whether a patient is likely to benefit from treatment based on imaging and clinical findings.

Syfovre and Izervay are administered as intravitreal injections, meaning the medication is injected directly into the vitreous cavity of the eye. The procedure is performed in the office by a specialist under sterile conditions.

Before the injection, the eye is numbed with anesthetic drops and cleaned with antiseptic to reduce the risk of infection. The injection itself takes only a few seconds. Most patients feel pressure rather than pain during the procedure.

These medications are not taken orally and cannot be delivered as eye drops. Direct injection into the eye allows the drug to reach the retina at therapeutic levels.

After the injection, patients are monitored briefly and can usually return home the same day. Mild redness, irritation, or temporary floaters may occur, but serious complications are uncommon.

The frequency of Syfovre or Izervay injections depends on the specific medication and your retina specialist’s recommendation.

Syfovre is FDA-approved for either monthly injections or injections every other month. Izervay is FDA-approved for monthly injections, although some retina specialists may extend the interval in carefully selected patients based on response and risk profile.

The injection schedule is determined by several factors, including the size and location of geographic atrophy, how quickly it is progressing, and how your retina responds to treatment over time. Regular retinal imaging is used to monitor changes and adjust the interval when appropriate.

Because geographic atrophy is a chronic condition, ongoing treatment is typically required to maintain the slowing effect of the medication.

Syfovre and Izervay are not designed to improve vision. Their primary purpose is to slow the progression of geographic atrophy in advanced dry macular degeneration.

These medications work by reducing the rate at which retinal cells are lost. By slowing the enlargement of blind spots in central vision, they help preserve the vision that remains. In clinical trials, the benefit was measured by reduced growth of atrophic areas rather than improvement in visual acuity.

Some patients may feel that their vision remains more stable over time compared to the expected natural progression of the disease. However, these treatments do not reverse existing retinal damage or restore vision that has already been lost.

The goal of therapy is preservation, not restoration. Slowing disease progression can help maintain independence and daily function for a longer period of time.

Syfovre and Izervay have been studied in large clinical trials and are considered generally safe when administered by a trained retina specialist. As with any intraocular injection, however, there are risks that patients should understand.

The most common side effects are mild and may include temporary redness, irritation, floaters, or small areas of surface bleeding on the eye. These symptoms typically resolve on their own.

Because these medications affect the complement system, they carry a known risk of developing wet macular degeneration during treatment. In clinical trials, wet AMD developed in approximately 7 to 12 percent of treated patients over two years, compared to about 3 percent in untreated groups. If wet AMD develops, it can be treated with anti-VEGF injections.

Rare but serious complications of any eye injection include infection inside the eye, known as endophthalmitis, inflammation, or retinal detachment. These events are uncommon but require immediate medical attention if symptoms such as severe pain or sudden vision loss occur.

Your retina specialist will carefully evaluate whether the benefits of slowing geographic atrophy outweigh the potential risks in your specific case.

Syfovre was approved by the U.S. Food and Drug Administration in February 2023 for the treatment of geographic atrophy secondary to dry age-related macular degeneration. It was the first FDA-approved medication specifically indicated for this condition.

Izervay was approved shortly afterward, in August 2023, also for the treatment of geographic atrophy due to dry macular degeneration. Its approval marked the second complement inhibitor available for this advanced stage of the disease.

The approval of these medications represented a major milestone in retina care, as they were the first treatments shown to slow the progression of geographic atrophy.

Yes, Medicare typically covers Syfovre and Izervay under Medicare Part B because they are physician-administered injectable medications given in a medical office setting.

Medicare generally covers 80 percent of the approved cost after the Part B deductible is met. If you have supplemental insurance, it may cover some or all of the remaining 20 percent. Coverage can vary depending on your specific plan and whether prior authorization is required.

Because these medications are relatively new and high-cost, retina offices usually perform a benefits investigation before starting treatment. This helps determine your out-of-pocket responsibility and whether additional co-pay assistance programs are available.

The cost of Syfovre and Izervay can vary depending on insurance coverage, geographic region, and individual treatment schedules. These are specialty medications, and the retail price per injection is typically several thousand dollars before insurance coverage.

For patients with Medicare Part B, Medicare generally covers 80 percent of the approved cost after the deductible is met. If you have supplemental insurance, it may cover some or all of the remaining balance. Commercial insurance plans may also provide coverage, but prior authorization is often required.

Because out-of-pocket costs can differ significantly between patients, retina practices typically perform a benefits investigation before starting treatment. In addition, manufacturer-sponsored patient assistance and co-pay support programs may be available to help reduce financial burden for eligible patients.

Before beginning therapy, your retina specialist’s office will review your coverage and discuss expected costs so you can make an informed decision about treatment.

The cost of Syfovre and Izervay can vary depending on insurance coverage, geographic region, and individual treatment schedules. These are specialty medications, and the retail price per injection is typically several thousand dollars before insurance coverage.

For patients with Medicare Part B, Medicare generally covers 80 percent of the approved cost after the deductible is met. If you have supplemental insurance, it may cover some or all of the remaining balance. Commercial insurance plans may also provide coverage, but prior authorization is often required.

Because out-of-pocket costs can differ significantly between patients, retina practices typically perform a benefits investigation before starting treatment. In addition, manufacturer-sponsored patient assistance and co-pay support programs may be available to help reduce financial burden for eligible patients.

Before beginning therapy, your retina specialist’s office will review your coverage and discuss expected costs so you can make an informed decision about treatment.

Syfovre is pronounced ‘Sigh-fove-ree’.
Izervay is procounced ‘eye-zer-vay